Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This analysis of localized appendiceal adenocarcinoma reveals low relapse rates post-resection, identifies key histopathologic and molecular relapse predictors, and finds no significant benefit from adjuvant chemotherapy, challenging conven
Adjuvant chemotherapy shows survival benefits in select subgroups of distal bile duct carcinoma patients post-surgery, emphasizing the need for tailored treatment strategies and further prospective research.
This study reveals that circulating tumor DNA (ctDNA) status after colorectal liver metastasis surgery predicts survival outcomes and benefits from adjuvant chemotherapy, guiding personalized treatment.
A 10-year randomized trial reveals that replacing anthracyclines with capecitabine (TCX) significantly improves overall survival and reduces toxicity compared to the standard TAC regimen in high-risk, HER2-negative breast cancer patients.
The randomized phase 2/3 DYNAMIC-III trial shows that postoperative circulating tumor DNA (ctDNA) strongly stratifies recurrence risk in stage III colon cancer. ctDNA-guided de-escalation reduced oxaliplatin exposure and hospitalizations wi
Comprehensive proteogenomic profiling in resected extrahepatic cholangiocarcinoma reveals predictive biomarkers for tailoring adjuvant chemotherapy, offering a precision medicine approach to improve patient outcomes.
A rigorous pooled analysis of over 35,000 patients identifies a recurrence risk below 0.5% at 6 years post-surgery, providing a practical benchmark for defining cure in stage II-III colon cancer and refining patient management strategies.
Monitoring circulating tumor DNA (ctDNA) post-surgery accurately predicts recurrence risk in extrahepatic cholangiocarcinoma, guiding personalized adjuvant chemotherapy decisions and improving patient outcomes.
This phase 3 trial compares induction-concurrent chemotherapy with concurrent-adjuvant chemotherapy in high-risk N2 to N3 nasopharyngeal carcinoma, finding no significant difference in 3-year progression-free survival while highlighting dis
A phase 3 trial showed no significant difference in 3-year progression-free survival between induction-concurrent and concurrent-adjuvant chemoradiotherapy in treating high-risk N2-N3 nasopharyngeal carcinoma, with both regimens exhibiting
A 3-year structured exercise program post-adjuvant chemotherapy significantly improves disease-free and overall survival in colon cancer patients, based on the CHALLENGE phase 3 RCT involving 889 patients.
The ASTER 70s trial found that adding chemotherapy to hormonotherapy did not improve survival but increased toxicity in women aged 70+ with high-risk ER+/HER2- breast cancer.